HENGJR
2021-09-14
help like pls
Here's Why Ocugen Is Skyrocketing On Monday<blockquote>这就是Ocugen周一飙升的原因</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
8
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":886583897,"tweetId":"886583897","gmtCreate":1631605326019,"gmtModify":1631889296019,"author":{"id":3578460931764306,"idStr":"3578460931764306","authorId":3578460931764306,"authorIdStr":"3578460931764306","name":"HENGJR","avatar":"https://static.tigerbbs.com/0596e746d9a22ec6462910c02c3129ce","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>help like pls</p></body></html>","htmlText":"<html><head></head><body><p>help like pls</p></body></html>","text":"help like pls","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/886583897","repostId":1133790240,"repostType":4,"repost":{"id":"1133790240","kind":"news","pubTimestamp":1631605138,"share":"https://www.laohu8.com/m/news/1133790240?lang=zh_CN&edition=full","pubTime":"2021-09-14 15:38","market":"us","language":"en","title":"Here's Why Ocugen Is Skyrocketing On Monday<blockquote>这就是Ocugen周一飙升的原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133790240","media":"Motley Fool","summary":"There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(N","content":"<p>There's both good and bad news for this troubled coronavirus vaccine biotech.</p><p><blockquote>对于这种陷入困境的冠状病毒疫苗生物技术公司来说，既有好消息也有坏消息。</blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> <b>Ocugen</b>(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.</p><p><blockquote><b>奥库根</b>（纳斯达克：OCGN）周一股价放量飙升15.8%，至每股8.28美元，消息人士告诉印度通讯社亚洲新闻国际，世界卫生组织可能会在本周批准印度冠状病毒疫苗Covaxin的紧急使用上市。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> An EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.</p><p><blockquote>世卫组织的EUL将为世界各地更多监管机构批准科瓦克辛提供可信度。在临床试验中，该疫苗对有症状的新冠肺炎（包括由变异毒株引起的病例）表现出77.8%的有效性。总部位于印度的Bharat Biotech拥有科瓦克辛的全球商业化权利，但在美国和加拿大除外，该公司将其授权给了Ocugen。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/303e002c71ec48a633f9aeed23a7c925\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> While the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.</p><p><blockquote>虽然世卫组织的进展是个好消息，但请记住，Ocugen是一家处于研究阶段的生物技术公司，没有后期候选产品，甚至不拥有科瓦克辛。更糟糕的是，该公司一直在向美国寻求生物制剂许可申请。美国食品药品监督管理局自6月起批准，这将需要很长时间，还需要额外的临床试验来支持该申请。如果这还不够，这家合资企业一半的利润将归巴拉特生物技术公司所有。</blockquote></p><p> The company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of approved alternatives available, it's best to be careful around Ocugen's stock.</p><p><blockquote>该公司的市值已飙升至15亿美元——尽管它只计划在美国销售1亿剂科瓦克辛。在有大量经批准的替代品可用的时候，最好小心Ocugen的股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Ocugen Is Skyrocketing On Monday<blockquote>这就是Ocugen周一飙升的原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Ocugen Is Skyrocketing On Monday<blockquote>这就是Ocugen周一飙升的原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-14 15:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p>There's both good and bad news for this troubled coronavirus vaccine biotech.</p><p><blockquote>对于这种陷入困境的冠状病毒疫苗生物技术公司来说，既有好消息也有坏消息。</blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> <b>Ocugen</b>(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.</p><p><blockquote><b>奥库根</b>（纳斯达克：OCGN）周一股价放量飙升15.8%，至每股8.28美元，消息人士告诉印度通讯社亚洲新闻国际，世界卫生组织可能会在本周批准印度冠状病毒疫苗Covaxin的紧急使用上市。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> An EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.</p><p><blockquote>世卫组织的EUL将为世界各地更多监管机构批准科瓦克辛提供可信度。在临床试验中，该疫苗对有症状的新冠肺炎（包括由变异毒株引起的病例）表现出77.8%的有效性。总部位于印度的Bharat Biotech拥有科瓦克辛的全球商业化权利，但在美国和加拿大除外，该公司将其授权给了Ocugen。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/303e002c71ec48a633f9aeed23a7c925\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> While the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.</p><p><blockquote>虽然世卫组织的进展是个好消息，但请记住，Ocugen是一家处于研究阶段的生物技术公司，没有后期候选产品，甚至不拥有科瓦克辛。更糟糕的是，该公司一直在向美国寻求生物制剂许可申请。美国食品药品监督管理局自6月起批准，这将需要很长时间，还需要额外的临床试验来支持该申请。如果这还不够，这家合资企业一半的利润将归巴拉特生物技术公司所有。</blockquote></p><p> The company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of approved alternatives available, it's best to be careful around Ocugen's stock.</p><p><blockquote>该公司的市值已飙升至15亿美元——尽管它只计划在美国销售1亿剂科瓦克辛。在有大量经批准的替代品可用的时候，最好小心Ocugen的股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133790240","content_text":"There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.\nSo what\nAn EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.\nIMAGE SOURCE: GETTY IMAGES.\nNow what\nWhile the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.\nThe company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of approved alternatives available, it's best to be careful around Ocugen's stock.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":291,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/886583897"}
精彩评论